Want to see GANX full AI Analyst Report?
GANX Stock Chart & Stats
$1.90
-$0.07(-3.85%)
At close: 4:00 PM EDT
$1.90
-$0.07(-3.85%)
Day’s Range― - ―
52-Week Range$1.15 - $4.34
Previous Close$1.75
Volume471.96K
Average Volume (3M)474.83K
Market Cap
$51.94M
Enterprise Value$74.57M
Total Cash (Recent Filing)$13.08M
Total Debt (Recent Filing)$609.87K
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Nov 18, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding43,643,620
10 Day Avg. Volume518,941
30 Day Avg. Volume474,828
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)5.72
Price to Sales (P/S)0.00
P/FCF Ratio-5.75
Enterprise Value/Market Cap1.44
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.90
Forecast
1Y Price Target
$7.20Price Target Upside278.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.5
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Precision-medicine PlatformGain Therapeutics has a focused discovery approach aimed at protein-misfolding diseases, using the Magnet computational platform to identify precision medicines. This gives the company a coherent scientific strategy and a basis for developing multiple candidates in CNS disorders over time.
Low Financial LeverageLow debt and positive equity reduce immediate leverage pressure and interest-related constraints, preserving more flexibility for clinical development. This balance-sheet profile provides some resilience while the company advances its pipeline, even though continued losses remain a concern.
Promising Parkinson’s Clinical DataThe 12-month open-label data provide supportive evidence for rexaceract, including stable motor scores, a favorable biomarker response in high-baseline patients, and sustained tolerability. These findings support the planned Phase 2 protocol and potential advancement of the lead program.
Bears Say
Minimal Revenue And Persistent LossesThe company has not yet generated meaningful revenue and remains deeply unprofitable, limiting internal funding capacity and demonstrating that its business model still depends on successful clinical development. Persistent losses may continue until a product or partnership generates commercial income.
Sustained Cash BurnConsistently negative operating and free cash flow show that Gain Therapeutics is not self-funding its operations or clinical programs. Continued burn creates an ongoing need to secure external capital, which can constrain development plans and increase dilution risk if losses persist.
Finance Leadership TransitionThe departure of the finance chief and temporary consolidation of CEO and CFO responsibilities introduce an execution and oversight transition. Although the company stated the interim appointment supports continuity, a permanent finance leader still needs to be recruited during an intensive development phase.
Gain Therapeutics News
GANX FAQ
What was Gain Therapeutics’s price range in the past 12 months?
Gain Therapeutics lowest stock price was $1.15 and its highest was $4.34 in the past 12 months.
What is Gain Therapeutics’s market cap?
Gain Therapeutics’s market cap is $51.94M.
When is Gain Therapeutics’s upcoming earnings report date?
Gain Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 27 days.
How were Gain Therapeutics’s earnings last quarter?
Gain Therapeutics released its earnings results on Aug 11, 2026. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.138 by $0.028.
Is Gain Therapeutics overvalued?
According to Wall Street analysts Gain Therapeutics’s price is currently Undervalued.
Does Gain Therapeutics pay dividends?
Gain Therapeutics does not currently pay dividends.
What is Gain Therapeutics’s EPS estimate?
Gain Therapeutics’s EPS estimate is -0.13.
How many shares outstanding does Gain Therapeutics have?
Gain Therapeutics has 43,643,620 shares outstanding.
What happened to Gain Therapeutics’s price movement after its last earnings report?
Gain Therapeutics reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.138. Following the earnings report the stock price went up 16.384%.
Which hedge fund is a major shareholder of Gain Therapeutics?
Currently, no hedge funds are holding shares in GANX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gain Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.20 (278.95% Upside)
$7.20 (278.95% Upside)
Blogger Sentiment
Bullish
GANX Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 176.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.33%
12-Months-Change
Fundamentals
Return on Equity
-161.58%
Trailing 12-Months
Asset Growth
56.82%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Gain Therapeutics
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
GANX Stock 12 Month Forecast
Average Price Target
$7.20
▲(278.95% Upside)
Technical Analysis
Ownership Overview
2.23%
Insiders
1.72% Mutual Funds
0.08% Other Institutional Investors
94.44% Public Companies and
Individual Investors